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ABSTRACT
Diversity in colorectal cancer biology is associated with variable responses to 
standard chemotherapy. We aimed to identify and validate DNA hypermethylated 
genes as predictive biomarkers for irinotecan treatment of metastatic CRC patients.
Candidate genes were selected from 389 genes involved in DNA Damage Repair 
by correlation analyses between gene methylation status and drug response in 32 cell 
lines. A large series of samples (n=818) from two phase III clinical trials was used 
to evaluate these candidate genes by correlating methylation status to progression-
free survival after treatment with first-line single-agent fluorouracil (Capecitabine 
or 5-fluorouracil) or combination chemotherapy (Capecitabine or 5-fluorouracil plus 
irinotecan (CAPIRI/FOLFIRI)).
In the discovery (n=185) and initial validation set (n=166), patients with 
methylated Decoy Receptor 1 (DCR1) did not benefit from CAPIRI over Capecitabine 
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treatment (discovery set: HR=1.2 (95%CI 0.7-1.9, p=0.6), validation set: HR=0.9 
(95%CI 0.6-1.4, p=0.5)), whereas patients with unmethylated DCR1 did (discovery 
set: HR=0.4 (95%CI 0.3-0.6, p=0.00001), validation set: HR=0.5 (95%CI 0.3-0.7, 
p=0.0008)). These results could not be replicated in the external data set (n=467), 
where a similar effect size was found in patients with methylated and unmethylated 
DCR1 for FOLFIRI over 5FU treatment (methylated DCR1: HR=0.7 (95%CI 0.5-0.9, 
p=0.01), unmethylated DCR1: HR=0.8 (95%CI 0.6-1.2, p=0.4)).
In conclusion, DCR1 promoter hypermethylation status is a potential predictive 
biomarker for response to treatment with irinotecan, when combined with 
capecitabine. This finding could not be replicated in an external validation set, in 
which irinotecan was combined with 5FU. These results underline the challenge and 
importance of extensive clinical evaluation of candidate biomarkers in multiple trials.
INTRODUCTION
The outcome of patients with colorectal cancer (CRC) 
strongly depends on tumor stage at time of diagnosis. Whereas 
stage I CRC patients have a 5-year overall survival of more 
than 90%, in stage IV CRC patients it declines to ~20% or less 
[1]. When unresectable distant metastases develop, palliative 
systemic therapy is the only treatment option available to 
these patients. The backbone of this is a fluoropyrimidine, e.g. 
capecitabine (CAP) or 5-fluorouracil (5-FU) in combination 
with either oxaliplatin or irinotecan [2]. Addition of targeted 
agents directed against vascular epithelial growth factor 
(VEGF) (bevacizumab) or epidermal growth factor receptor 
(EGFR) (cetuximab and panitumumab) has been demonstrated 
to give additional outcome benefit.[3] Only a subset of patients 
benefit from these regimens, while those patients that do not, 
may still suffer from considerable toxicity. With the exception 
of KRAS/NRAS mutation status that predicts resistance to 
EGFR-targeted therapy [4, 5], no other biomarkers exist that 
adequately predict treatment response in metastatic CRC. 
Thus, predictive biomarkers are urgently needed to identify the 
subset of patients who will benefit from a specific treatment.
Hypermethylated genes form a particular category 
of biomarkers and a number of these have been reported 
to predict drug response in CRC patients [6, 7]. but 
inconsistent results for the same markers have been 
reported [8, 9]. Hypermethylated genes are of particular 
interest, since DNA methylation is potentially reversible 
by DNA methyltransferase inhibitors, which could 
provide a way to restore expression of genes silenced by 
DNA hypermethylation and thus increase the sensitivity 
of tumor cells to the agents the gene is associated with 
[10, 11].
In the present study we set out to identify and 
validate novel hypermethylated genes that could 
potentially predict response to treatment with irinotecan 
in patients with metastatic CRC, using material from two 
clinical trials, i.e. the Dutch CApecitabine, IRinotecan 
and Oxaliplatin (CAIRO) study [12] and the Fluorouracil, 
Oxaliplatin, CPT-11: Use and Sequencing (FOCUS-1) 
study from the UK [13].
RESULTS
Candidate gene selection
Correlation analyses of the DNA methylation status 
with drug sensitivity in 32 cell lines yielded 22 genes 
associated with topoisomerase inhibitor-related mode of 
action. These genes were analyzed for DNA methylation 
status in the discovery set (n=185). Methylation frequencies 
ranged from 1% to 98%, average 43% (Table 1).
Evaluation of biomarker potential in the 
discovery set (CAIRO)
In concordance with the original CAIRO study [12], 
the sub selection of patients in the discovery set showed 
significantly longer PFS when treated with CAPIRI (n=95) 
compared to CAP alone (n=90) (median PFS of 252 vs 182 
days for CAPIRI vs CAP, respectively; HR=0.67 (95% CI 
0.50-0.90, p=0.007) (Figure 1A). DCR1 was methylated 
in 72/185 (39%) tumors. To assess the predictive value of 
each candidate gene, a multivariate survival model was 
generated including clinical variables, treatment arm, and 
an interaction term between treatment arm and candidate 
gene. After correcting for multiple testing, the treatment 
arm*candidate gene interaction remained significant for 
Tumor Necrosis Factor Receptor Superfamily member 
10c (TNFRSF10c, also known as Decoy Receptor 1 
(DCR1)) and Interleukin-1 Receptor-Associated Kinase 1 
(IRAK1). This indicates that the methylation status of these 
candidate genes exerted an independent effect on PFS that 
was different between treatment arms (Table 2).
Kaplan-Meyer curve analysis revealed that out of the 
two final candidate genes, the methylation status of DCR1 
was predictive for PFS after treatment with CAPIRI, but not 
for PFS after treatment with CAP; patients with methylated 
DCR1 tumors progressed more quickly than patients with 
unmethylated DCR1 tumors when treated with CAPIRI 
(HR=2.1 (95% CI 1.3-3.3, p=0.001), but no difference was 
observed between patients with unmethylated or methylated 
DCR1 tumors when treated with CAP (HR=0.7 (95% CI 0.5-1.1, 
p=0.1) (Supplementary Figure 1). IRAK1 methylation was 
Oncotarget63142www.impactjournals.com/oncotarget
predictive of PFS after treatment with CAP, but not for CAPIRI 
(Supplementary Figure 1), and hence was not further studied.
Because CAIRO was a randomized controlled trial, 
we were able to estimate the benefit of CAPIRI treatment 
over CAP treatment for patients with methylated or 
unmethylated DCR1 tumors by comparing PFS between 
the different treatment arms. Patients with methylated 
DCR1 (72 out of 185; 39%) did not benefit from adding 
irinotecan to CAP (median PFS of 192 vs 184 days for 
CAPIRI vs CAP, respectively; HR=1.2 (95%CI 0.7-1.9, 
p=0.6; Figure 1B)). In contrast, patients with unmethylated 
DCR1 showed a significantly longer PFS when treated 
with CAPIRI compared to CAP alone (median PFS of 270 
vs 178 days for CAPIRI vs CAP, respectively; HR=0.4 
(95% CI 0.3-0.6, p=0.00001; Figure 1C)).
Internal validation set (CAIRO)
In the second set of patients from the CAIRO study, in 
concordance with the original CAIRO study [12], PFS was 
significantly longer for patients treated with CAPIRI (n=88) 
compared to patients treated with CAP alone (n=78) (median 
PFS of 267 vs 200 days for CAPIRI vs CAP, respectively; 
HR=0.6 (95% CI 0.5-0.9, p=0.003; Figure 2A)).
DCR1 was methylated in 88 out of 166 (53%) 
tumors. A multivariate analysis, as described for 
the discovery set, showed a significant interaction 
between treatment arm and DCR1 methylation (p=0.04, 
Table 3 ). Kaplan-Meyer analyses confirmed that patients 
with methylated DCR1 tumors did not significantly benefit 
from CAPIRI treatment over CAP treatment (median PFS 
of 267 vs 203 days for CAPIRI vs CAP, respectively; 
HR=0.9 (95%CI 0.6-1.4, p=0.5; Figure 2B)), whereas 
patients with unmethylated DCR1 tumors did (median 
PFS of 261 vs 195 days for CAPIRI vs CAP, respectively; 
HR=0.5 (95%CI 0.3-0.7, p=0.0008) (Figure 2C)).
External validation set (FOCUS)
As an independent validation series, we analyzed 
467 tumor samples from another randomized controlled 
phase III clinical trial (FOCUS) [13]. In this series, 
similar to the original trial, PFS was significantly longer 
for patients treated with FOLFIRI (n=136) compared to 
patients treated with 5-FU alone (n=331) (median PFS 
of 272 vs 231 days for FOLFIRI vs 5-FU, respectively; 
HR=0.8 (95%CI 0.6-1.0, p=0.02); Figure 3A).
DCR1 was methylated in 225 out of 467 (48%) 
tumors. Multivariate analysis revealed that there was 
no significant interaction between treatment arm and 
DCR1 methylation status (p=0.3, Table 3). Indeed, 
Kaplan-Meyer analyses revealed that patients with 
methylated or unmethylated DCR1 had a similar effect 
size from FOLFIRI treatment over 5-FU treatment, as 
based on HR (methylated DCR1: median PFS of 283 vs 
225 days for FOLFIRI vs 5-FU, respectively; HR=0.7 
(95%CI 0.5-0.9, p=0.01) (Figure 3B); unmethylated 
DCR1: median PFS of 253 vs 235 days for FOLFIRI 
vs 5-FU, respectively; HR=0.8 (95%CI 0.6-1.2, p=0.4) 
(Figure 3C).
Methylation of DCR1 is associated to decreased 
gene expression
The relation between DCR1 promoter 
hypermethylation and gene expression was investigated 
in vitro in a panel of 13 CRC cell lines. Ten out of 13 
CRC cell lines were fully methylated for DCR1 and 
showed low or absent gene expression. The other three 
CRC cell lines were hemi-methylated and showed clearly 
higher gene expression levels (Figure 4A). Treatment 
of two CRC cell lines, HCT116 and Colo205, with the 
demethylating agent DAC resulted in increased DCR1 
Table 1: Discovery set: observed methylation 
frequencies of candidate genes
Gene symbol Methylation frequency 
in the discovery set 
(n=185)
BIK 27%
CAT 14%
CCND2 31%
CDK5 17%
DAPK1 23%
DCR1 39%
EEF1A2 (primer set 1) 1%
EEF1A2 (primer set 2) 5%
HOXA9 40%
IRAK1 40%
LIG4 92%
NUDT1 92%
PAX3 (primer set 1) 85%
PAX3 (primer set 2) 98%
PRKCB1 23%
PROK2 19%
PROP1 93%
PTGS2 8%
RASSF1 14%
RBBP8 45%
RHOB 4%
SPO11 96%
TBX5 96%
TIPARP 19%
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Figure 1: CAIRO discovery set: Progression-free survival Progression free survival in metastatic CRC cancer patients 
treated in first-line with CAP (dashed line) or CAPIRI (solid line)in (A) all patients from the CAIRO discovery set, in 
(B) patientswith methylated tumor DCR1or in (C) patients with unmethylated tumor DCR1. 95% confidence interval of 
the survival probability is shown by dark and light grey shades. HR=Hazard Ratio (CAPIRI versus CAP).
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expression (p=0.005 and p=0.08, respectively; Figure 4B). 
In addition, data from The Cancer Genome Atlas (TCGA) 
database (http://cancergenome.nih.gov), including 223 
CRC tumors, confirmed a negative correlation between 
DCR1 DNA methylation and DCR1 mRNA expression 
(Pearson correlation of -0.4, p=3.4E-9; Figure 4C).
DISCUSSION
In the present study we used a candidate gene 
approach to identify methylation markers for response to 
treatment with irinotecan-based therapy. We first made 
a selection of candidate genes based on in vitro findings 
on their function in relation to the mode of action of 
irinotecan, i.e. topoisomerase inhibition. Next, we tested 
for correlation of the methylation status of the candidate 
genes and PFS after treatment with CAPIRI therapy of 
metastatic CRC patients participating to the phase III 
CAIRO trial [12], which identified DCR1 as a candidate 
marker. Because patients treated with CAP alone were 
used as a control group, this analysis showed DCR1 
methylation as a potential negative predictive marker for 
response to irinotecan-based therapy. The initial finding in 
the discovery set could be confirmed in a second series of 
patients from the same CAIRO study, which indicated that 
the initial finding was not a stochastic statistical finding. 
Table 2: Multivariate analysis for predictive value of candidate genes, showing p-values (size) and Hazard Ratio’s (color).
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Figure 2: CAIRO validation set: Progression-free survival Progression free survival in metastatic CRC cancer patients 
treated in first-line with CAP (dashed line) or CAPIRI (solid line)in (A) all patients from the CAIRO validation set, in 
(B) patientswith methylated tumor DCR1or in (C) patients with unmethylated tumor DCR1. 95% confidence interval of 
the survival probability is shown by dark and light grey shades. HR=Hazard Ratio (CAPIRI versus CAP).
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However, validation in a second, independent series 
of metastatic CRC patients from the phase III FOCUS 
trial [13], treated with first-line FOLFIRI or 5-FU alone, 
did not confirm DCR1 methylation status as negative 
predictive marker for response to irinotecan-based therapy.
Developing predictive biomarkers that reach the 
phase of introduction into clinical practice has proven 
to be highly challenging. The literature is full of proof 
of concept publications on potential biomarkers, but 
in most instances no further validation follows or if 
so they fail to publish. The current study was carefully 
designed in order to overcome most common pitfalls 
in biomarker discovery [14, 15]; i.e. a strong biological 
rationale existed for the preselected candidate genes, 
and extensive evaluation (discovery, internal validation 
and external validation) was performed in a prospective-
retrospective design [16] on a total of 818 archival tumor 
samples derived from two similar well-conducted phase 
III randomized clinical trials, providing the highest quality 
of clinical annotation [12, 13] In addition, both clinical 
trials included a control group (i.e. CAP as control group 
for CAPIRI and 5-FU as control group for FOLFIRI), 
which is required to distinguish predictive from prognostic 
markers. Furthermore, biomarker independence was tested 
by including potential confounding factors in the statistical 
models. Nonetheless, after initial validation in a second 
sub-sample of the CAIRO study, we could not validate 
DCR1 methylation as a negative predictive marker for 
response to irinotecan-based therapy in the independent 
patient series from FOCUS. A lack of correlation between 
DCR1 methylation and DCR1 gene expression could be 
one of the reasons why DCR1 methylation as a marker 
for response to irinotecan-based therapy did not validate. 
However, our cell-line experiments as well as analysis 
of a large series from the TCGA database did show a 
correlation between DCR1 DNA methylation and gene 
expression silencing. All this data together would suggest 
to simply discard DCR1 methylation as a potential 
biomarker for response to irinotecan-based therapy, 
although our findings could still be otherwise explained. 
The two trials for instance, while they show substantial 
resemblances at first glance, differ in a number of features 
related to inclusion (e.g. the performance scores leading 
to differences in patient characteristics), population 
differences (methylation varies between populations 
and races [17]) and importantly treatment (e.g. different 
backbone treatment; CAP versus 5-FU). 5-FU, in contrast 
to CAP, is given in combination with Leucovorin, which is 
a reduced folic acid. Folic acid is implicated in regulation 
of DNA methylation and aberrant folic acid levels may 
affect global or site-specific DNA methylation levels in 
tissues [18, 19]. Treatment with Leucovorin thus could 
potentially affect DNA methylation levels in tumor tissue 
over time and thereby influencing the association with 
an a priori measured DNA methylation marker and drug 
sensitivity.
The current study has some limitations. For 
example, the drug-response screen on candidate genes 
was performed on cell lines rather than on actual human 
tumor samples. Although the use of cell lines reduces the 
number of confounding factors as compared to human 
tumor samples, it remains a challenge to translate the 
relevance of the observed data to the in vivo situation [20], 
and other interesting genes might have been missed by this 
approach.
Another limitation of the current study is that 
measurements were performed on samples from the primary 
tumor, while patients were treated for their metastases, 
raising the question whether intra tumor heterogeneity could 
play a role. Although metastases can acquire additional 
Table 3: Evaluation of predictive value of DCR1 methylation on progression after treatment(multivariate cox 
proportional hazard model)
Variables in the model CAIRO discovery set CAIRO validation set FOCUS validation set
HR p-value HR p-value HR p-value
Treatment 0.4 0.00002 0.4 0.0001 0.9 0.4
DCR1 methylation status 0.6 0.05 0.8 0.3 1.1 0.6
Age 1.0 0.8 1.0 0.03 1.0 0.05
Gender 0.7 0.05 1.0 0.9 0.9 0.5
WHO performance status 1.1 0.5 1.1 0.5 1.0 0.8
Previous adjuvant therapy 1.5 0.04 1.2 0.5 1.1 0.6
LDH 1.7 0.002 1.5 0.02 na na
location of metastases 1.4 0.07 0.8 0.2 na na
Interaction treatment*DCR1 methylation 
status
2.9 0.0008 2.0 0.04 0.8 0.3
HR = hazard ratio
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Figure 3: FOCUS validation set: Progression-free survival Progression free survival in metastatic CRC cancer patients 
treated in first-line with 5-FU (dashed line) or FOLFIRI (solid line)in (A) all patients from the FOCUS validation set, 
in (B) patientswith methylated tumor DCR1or in (C) patients with unmethylated tumor DCR1. 95% confidence interval of 
the survival probability is shown by dark and light grey shades. HR=Hazard Ratio (FOLFIRI versus 5-FU).
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Figure 4: DCR1 methylation and mRNA expression levels (A) DCR1 mRNA expression analysis in CRC cell lines by RT-
PCR. DCR1 DNA methylation percentage as measured by qMSP (M%) is indicated below each cell line. Quantifications represent mean 
expression values from three independent experiments. (B) DCR1 mRNA expression analysis by RT-PCR of HCT116 (left panel) and 
Colo205 (right panel) with and without DAC treatment (p=0.005 and p=0.08, respectively). (C) Scatter plot including a linear regression 
line and 95% confidence interval, showing the correlation of DCR1 methylation levels and DCR1 mRNA expression in 223 CRC tissues 
from TCGA.
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genomic alterations, they keep most of the alterations 
present in the primary tumor [21, 22]. As DNA methylation 
is usually an early event in colorectal carcinogenesis, this is 
likely to be the case here as well [23].
Lastly, DCR1 methylation analyses were performed 
with identical primers but with different reagents in 
different laboratories for the three study cohorts. This 
could have introduced variability in test results. The 
proportion of patients having a positive test result was 
slightly different for the three cohorts indeed (39% in 
the discovery set, 53% in the internal validation set and 
48% in the external validation set). However, because 
the predictive value of DCR1 methylation with regard to 
irinotecan-based therapy showed similar results in the two 
cohorts with largest relative difference in prevalence of 
methylation (39% vs 53%), this variability is not likely to 
Table 4: MSP primer sequences
Lightcycler MSP primers
Name S primer AS primer
BIK TTTTTGGAGTTTCGGTTTTTAC CTTTACACGAATAACCTCCGTTC
CAT GTTTGTTGTTTCGAGTTCGTG ATCTTAACCTACCTAACGCCGA
CCND2 CGGGGTTGTTTTATTCGTATCG CAACCAACTTACGTCACCGCT
CDK5 AGTTTTGCGGGAAATGTTAATAC AAACTCCGATCTCAACAACGA
DAPK1 TAAGGAGTCGAGAGGTTGTTTC CCTACCGCTACGAATTACCGA
DCR1 TTACGCGTACGAATTTAGTTAAC CATCAAACGACCGAAACG
EEF1A2 (1) GTTCGTGATTAGTAGAGTCGGGT ACAACGAATAAAAATAAAACGCC
EEF1A2 (2) TTAGGTTGGGTACGTTCGTGA ACAACGAATAAAAATAAAACGCC
HOXA9 AGGAGCGTATGTATTTGTCGTTC AACGCTATACCCGCTACGATA
IRAK1 AGGATGTGTACGAGGTCGGTT CGAACTACGACTATACGAACGCT
LIG4 GAGTTAAAAACGGGAGAAATCGT CACAACGCTATAAACTACGCC
NUDT1 GTATTTTTCGAGTTCGTTACGTTT TCCTCTTAACGTCCAACGAC
PAX3 (1) TTTGGGTATAGCGTCGGTT ATTCCCGAAAATCATCCGC
PAX3 (2) ATAGTTTTCGAGGGTTATTCGC CCTAAACACAACGCCGACC
PRKCB1 GTATCGCGTTTAGGTTTCGTTT CCGACGCTACAAAACTACGA
PROK2 ATAAAGGTTAGTTTCGTCGTGA ACACGTACTCGTCTAAAAACCG
PROP1 CGAGTTATGGAAGTAGAAAGGAGGC ATAATCGAAATCCCAATAACCGA
PTGS2 TTACGGAAATGAGAAAATCGG GCCTAAAACGATAAAACTCGAAA
RASSF1 GCGTATTGTAGGTTTTTGCGT TAATCCCTAACCGTAACCACCG
RBBP8 GTATTTTTATACGGGTAAGGCGA TACCCCGCTACTCTACTCCGC
RHOB AGGAGGGGATTCGGGTATC TAATTAACGACCCAAACCG
SPO11 AGTGTGGGTCGCGTAGGTATC CTAAATCCAATATCCGCAACACG
TBX5 TCGGTATTGATAGGCGAAGAC CTATAAAACTTAAAAACGTCACGAA
TIPARP TAAGGTTTACGAAATAGTCGGTC ACTACCACCAAACGAAATCGC
Beta Actin TAGGGAGTATATAGGTTGGGGAAGTT AACACACAATAACAAACACAAATTCAC
qMSP primers
Name S primer AS primer
Beta Actin TGGTGATGGAGGAGGTTTAGTAAGT GAATTTTTTTATGTGTATGAATTTAGTTAAT
DCR1_U GAATTTTTTTATGTGTATGAATTTAGTTAAT CCATCAAACAACCAAAACA
DCR1_M TTACGCGTACGAATTTAGTTAAC CATCAAACGACCGAAACG
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be the cause of the inability to validate DCR1 methylation 
as a predictive biomarker.
Another challenge is the biological complexity 
underlying tumor response to treatments and the question 
if a single biomarker can capture responses of a system 
as a whole. Moreover, the biology of DCR1, which acts 
in the TRAIL pathway, is complex. In normal tissue 
DCR1 is thought to work as a decoy receptor for the TNF-
related apoptosis-inducing ligand (TRAIL), thus having 
an anti-apoptotic effect in the TRAIL pathway [24]. There 
are some indications, however, that TRAIL receptors in 
cancer have an anti-apoptotic role via the NF-кB survival 
pathway and hence silencing of DCR1 would subject a 
cancer cell to a pro-survival and pro-growth signal [25, 
26] . The latter supports our finding in the CAIRO study 
that patients with a methylated DCR1 tumor have a worse 
outcome. Although our candidate gene selection revealed 
that DCR1 methylation is associated with sensitivity 
to topoisomerase inhibitor-related mode of action, the 
specific functional role of DCR1 methylation with regard 
to irinotecan is not known. It would be interesting to study 
this in colorectal cancer but because we could not validate 
DCR1 methylation as predictive marker for irinotecan 
treatment response, we feel that functional experimental 
analyses to dissect the role of DCR1 methylation and its 
interaction with irinotecan treatment are beyond the scope 
of the present study.
In conclusion, DCR1 methylation status was 
identified as a predictive marker for irinotecan-based 
therapy in metastatic colorectal cancer in both a 
discovery and an initial validation set. This could not be 
confirmed in an external validation data set, for which the 
difference in backbone treatments (5FU vs capecitabine) 
may possibly be an explanation. The present study 
highlights the challenge and importance of extensive 
evaluation of potential biomarkers. It also shows the 
complexity and extensiveness of systematic evaluation 
of a potential biomarker in order to generate more than 
just a proof of concept, and that a well-designed study is 
not a guarantee of success. Improvements in multi-team 
collaborations and in organizing data acquisition and 
biobanking in clinical trials will be necessary for efficient 
and successful discovery of predictive biomarkers in the 
future.
MATERIALS AND METHODS
Candidate gene selection
Candidate gene selection was based on correlations 
between methylation of 389 genes involved in DNA 
Damage Repair and Response and drug response in 32 cell 
lines, which is described in detail in the supplementary 
information. Because irinotecan is a topoisomerase-I 
inhibitor, genes associated sensitivity to topoisomerase 
inhibitor-related mode of action were considered.
Patient sample selection
Patients selected for the current study participated 
in either of two phase III trials, namely the CApecitabine, 
IRinotecan and Oxaliplatin (CAIRO) study of the Dutch 
Colorectal Cancer Group (DCCG) (CKTO 2002-07, 
ClinicalTrials.gov; NCT00312000) [12], and the Medical 
Research Council Fluorouracil, Oxaliplatin, CPT-11: Use 
and Sequencing (FOCUS) study (ISRCTN 79877428) 
under the auspices of the United Kingdom National 
Cancer Research Institute Colorectal Cancer Studies 
Group [13]. Written informed consent was required from 
all patients before study entry, and included consent for 
translational research on tumor tissue.
CAIRO biomarker populations
In the CAIRO study, 820 patients were 
randomized between sequential (arm-A, first-line CAP, 
second-line irinotecan and third-line CAPOX) and 
combination treatment (arm-B, first-line CAPIRI and 
second-line CAPOX). Patient and sample selection 
for molecular research purposes have been described 
before [27]. In short, we selected patients of whom 
FFPE tissue of the primary tumor was available 
through the Dutch national pathology registry PALGA 
[28]. Inherently these are the patients who underwent 
resection of the primary tumor (n=633), of which tissue 
samples were available for 478 patients. To be sure that 
the effect that we observed on outcome was related 
to the response to treatment and not to an unrelated 
intrinsic prognostic factor, patients that received only 
1 or 2 cycles of therapy were excluded. In order to 
prevent that we would lose early progressors that 
could still be related to treatment, we did include those 
patients that received 2 cycles when death followed due 
to progressive disease. These selection criteria left us 
with 425 tissue samples for further analysis. Finally, 
only tumors containing an area of at least 70% tumor 
cells were selected for DNA extraction, leaving 351 
tissue samples for further analysis DNA. The CAIRO 
discovery was done on a series of samples available 
that had been used in a previous study [27]. This series 
consisted of 185 patients, of which 90 patients were 
treated with first-line capecitabine (CAP) and 95 were 
treated with first-line capecitabine plus irinotecan 
(CAPIRI). The patient samples were matched according 
to the stratification factors in the original study (for 
the subgroup of patients that underwent resection of 
the primary tumor, since these are the patients from 
whom material was available to be included in this 
study) [12], that is, performance status, predominant 
metastatic site, previous adjuvant therapy and serum 
lactate dehydrogenase level (LDH).
For the initial validation set, patients were 
selected, with no further criteria, from the remaining 
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patients of which tumor DNA samples were available. 
These comprised 166 patients, of which 78 were treated 
with first-line CAP and 88 were treated with first-line 
CAPIRI.
FOCUS biomarker validation population
In the FOCUS study, 2135 patients without 
pretreatment were randomly assigned to three treatment 
strategies in the ratio 1:1:1. In strategy A (control group) 
patients received first-line 5FU, followed by second-line 
irinotecan. In strategy B patients received first-line 5FU, 
followed by second-line 5-FU plus irinotecan (FOLFIRI; 
Strategy B-ir) or 5-FU plus oxaliplatin (FOLFOX; strategy 
B-ox). In strategy C patients received FOLFIRI (C-ir) or 
FOLFOX (C-ox) from the outset. For the current study, 
patients from strategy A (first-line 5FU), strategy B-ir 
(first-line 5FU) and strategy C-ir (first-line FOLFIRI) were 
selected, for which a total of 515 tumor DNA samples 
were available. From these, patients treated with at least 
three cycles of first-line therapy were selected, leaving 
467 samples. These came from 331 patients treated with 
at least three cycles of first-line 5-FU (249 from strategy 
A and 82 from strategy B-ir) and 136 patients treated 
with at least three cycles of first-line 5-FU plus irinotecan 
(FOLFIRI; strategy C-ir).
DNA isolation and methylation analysis
Tumor samples from the CAIRO trial were retrieved 
through the Dutch national pathology registry PALGA 
[28] DNA was extracted from formalin-fixed paraffin-
embedded tissue samples of primary tumors, resected 
before chemotherapy, as described before. [29, 30] DNA 
concentrations were quantified using the Nanodrop 1000 
UV spectrophotometer (Nanodrop Technologies Inc, 
Wilmington, DE, USA). DNA was subjected to sodium 
bisulfite conversion using the EZ DNA Methylation Kit 
(Zymo Research, Orange, CA, USA) according to the 
manufacturer’s protocol.
Tumor DNA from the FOCUS trial was extracted 
as described in 7 [29]. DNA samples were subsequently 
cleaned by ethanol precipitation and DNA concentrations 
were quantified using the Nanodrop 1000 UV 
spectrophotometer (Nanodrop Technologies Inc).
All methylation assays were performed blind 
to information on treatment or survival outcome. The 
CAIRO discovery set was subjected to high-throughput 
LightCycler MSP assay (LightCycler 480 SYBR Green 
I Master kit (Roche, Vilvoorde, Belgium)) for the 22 
selected candidate genes. Primers were designed to 
promoter regions (i.e. -1000 to +200 bp relative to the 
transcription start site). Primers from the literature were 
used when they experimentally passed our quality control; 
see Table 4  for primer sequences. Quality control was 
performed with in vitro Methylated DNA (Chemicon, 
Temecula, CA) as a positive control and DNA from 
the unmethylated human HCT116 DKO cell line as a 
negative control. Per sample, 20 ng bisulfite-modified 
DNA was amplified with the following PCR conditions: 
95°C for 10 minutes followed by 45 cycles of 95°C for 10 
seconds, 60°C for 30 seconds and 72°C for one second. 
Amplification of beta-actin was used as an unmethylated 
reference gene. The amplicons were checked for size and 
quantified by capillary electrophoresis (LC90 Labchip; 
Caliper Lifesciences).
For the CAIRO validation set and CRC cell lines 
a quantitative MSP (qMSP) assay for DCR1 was used. 
The primers for methylated DNA were the same primer 
sequences as the primers used for LightCycler analyses 
described above and were designed at the exact location 
as described before [31]. qMSP reactions were carried out 
in duplicate in 25 μl reaction volumes, each containing 
36 ng of bisulfite-treated DNA, 10 pmol of each primer 
and 1x Power SYBR Green PCR Master Mix (Applied 
Biosystems, Foster City, CA). Each plate included no 
template controls and a standard curve with a serial 
dilution of bisulfite-modified DNA from a mixture of 
methylated cell line (HCT116) and unmethylated cell 
line (HCT116-DKO). PCR conditions were 95°C for 15 
minutes, followed by 40 cycles at 95°C for 30 seconds, 
56°C for 30 seconds and 72°C for 30 seconds, followed 
by a melt curve stage to check the specificity of the 
amplification reaction. Cycle threshold (Ct) values were 
measured at a fixed fluorescence threshold, which was 
always in the exponential phase of the amplification 
curves. The methylation percentage per sample was 
calculated according to the formula 2e-[mean CtM-
reaction]/(2e–[mean CtM-reaction]+2e-[mean CtU-
reaction])x100. The U (unmethylated) and M (methylated) 
reactions were amplified with comparable efficiencies. 
A sample was called methylated when the methylation 
percentage was higher than observed in a panel of 
21 normal colon mucosa from non-cancer patients as 
measured in triplicate (median plus two times the standard 
deviation = 6%).
The FOCUS validation set was analyzed with a 
qMSP assay for DCR1 as well. The primers for methylated 
DNA were equal to the primers used in the CAIRO 
discovery and validation study. qMSP reactions were 
carried out using a 7500 Fast Real-Time PCR System 
(Applied Biosystem,) in duplicate in 25 μl reaction 
volumes, where each reaction contained 40 ng of bisulfite-
treated DNA, 10 pmol of each primer and 12·5 μl SYBR 
Green PCR Master Mix (Applied Biosystems). Each plate 
included no-template controls and a standard curve with a 
serial dilution of bisulfite-modified DNA prepared from in 
vitro Methylated DNA (Chemicon). PCR conditions were 
95°C for 15 minutes, 40 cycles at 95°C for 15 seconds, 
60°C for 60 seconds, followed by melt curve analysis 
to check the specificity of the amplification reaction. 
Amplification of beta-actin was used as an unmethylated 
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reference gene, using the same PCR conditions. The Ct 
ratio per sample was calculated according to the formula 
2e-[mean CtDCR1 – mean CtACTB]. A sample was called 
methylated when the Ct ratio was higher than observed 
in a panel of 22 normal colon mucosa from non-cancer 
patients as measured in duplicate (median plus two times 
the standard deviation = 0·006)
Cell lines
HCT15, HCT116, LS513, LS174T, Colo320, 
SW48, SW1398, HT29, Colo205, SW480, and RKO were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM; 
Lonza Biowhittaker, Verviers, Belgium) containing 10% 
fetal bovine serum (Hyclone, Perbio, UK). Caco-2 was 
cultured in RPMI 1640 (Lonza Biowhittaker) containing 
20% fetal bovine serum. LIM1863 was cultured in 
RPMI 1640 (Lonza Biowhittaker) containing 5% FCS, 
0·01 mg/ml thioglycerol, 1 mg/ml insulin and 1 μg/ml 
hydrocortisone. All cell culture media were supplemented 
with 2 mM L-glutamine, 100 IU/ml sodium penicillin 
(Astellas Pharma B.V., Leiderdorp, The Netherlands) 
and 100 mg/ml streptomycin (Fisiopharma, Palomonta 
(SA), Italy). To investigate re-expression of DCR1 
after inhibition of DNA metyltransferases, HCT116 
and Colo205 cells were treated with 5000 nM 5-aza-2’-
deoxycytidine for three days (DAC, Sigma Chemical Co., 
St. Louis, MO, USA).
RNA isolation and qRT-PCR
Total RNA was isolated from cell lines using 
TriZol reagent (Invitrogen, Breda, the Netherlands), and 
subjected to purification using RNeasy Mini Kit (Qiagen). 
After DNAse treatment (RQ1 DNAse, Promega, Leiden, 
the Netherlands), cDNA was made with the Iscript cDNA 
Synthesis Kit (BioRad, Veenendaal, the Netherlands). 
Quantitative RT-PCR was done using TaqMan® Gene 
Expression Assays from Applied Biosystems directed 
to DCR1 (Hs00182570_m1) and a reference gene 
B2M (Hs00984230_m1). Relative expression levels 
were determined by calculating the Ct-ratio (Ct ratio = 
2e-(CtDCR1–CtB2M))x1000.
TCGA data
DCR1 DNA methylation (Illumina Infinium HM27 
bead array; HM27) and mRNA expression (Agilent 
array) data were obtained via cBioPortal for Cancer 
Genomics (http://www.cbioportal.org; [32]) on 223 
CRC tumors included in The Cancer Genome Atlas 
(TCGA) Colorectal Cancer project. This data set was 
downloaded on the 14th of July 2015 from all tumors 
with available methylation and mRNA expression data 
from the Colorectal Adenocarcinoma (TCGA, Nature 
2012) dataset [33].
Statistical analysis
The primary endpoint of the present study was 
progression free survival (PFS) under first-line systemic 
therapy with or without irinotecan. PFS for first-line 
treatment was calculated from the date of randomization 
to the first observation of disease progression or death 
reported after first-line treatment. To test the predictive 
value of candidate genes, multivariate Cox proportional 
hazard models were built that included the variables 
treatment, candidate gene and an interaction term 
treatment*candidate gene. In the CAIRO as well as the 
FOCUS trial, patients were randomized between treatment 
arms, which resulted in similar clinical characteristics 
between the treatment arms. However, because we 
were analyzing patient subsets from the original trials, 
for DCR1-specific analyses we corrected the estimates 
of predictive value for those variables that could have 
possible prognostic effect, by including them in the 
multivariate analyses. These were age, gender, WHO 
performance status and prior adjuvant therapy for both 
the CAIRO and the FOCUS samples, plus normal or 
abnormal LDH and location of metastases for CAIRO. 
Cox proportional hazard models were used to estimate 
Hazard Ratios (HR) and 95% confidence intervals (CI). 
Kaplan-Meier analyses and log-rank tests were used to 
estimate survival over time. Correction for multiple testing 
in the discovery set was done by the Benjamini Hochberg 
method.
Student’s T-test was used for comparison of DCR1 
expression levels before and after DAC treatment of 
HCT116 and Colo205. Pearson correlation analysis was 
used to measure correlation between DCR1 methylation 
and mRNA expression levels from 223 primary CRC 
tissue samples as provided by The Cancer Genome Atlas 
(TCGA) database.
Statistical analyses were performed using the 
computing environment R version 3.2 [34], including the 
packages survival and rms [35–37].
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